English
简体中文
Total: £ 56.28
Published Date: 2026-04-10 | Pages: 154 | Tables: 145 | Pharma & Healthcare
The global Microbiome Drugs market was valued at US$ 679 million in 2025 and is anticipated to reach US$ 4189 million by 2032, at a CAGR of 30.1% from 2026 to 2032.
Microbiome Drugs refer to a new class of therapeutic agents developed based on human commensal microbiota and their metabolites. These include live biotherapeutic products (LBPs), microbiota-derived metabolites, synthetic microbial formulations, and microbiome-targeted small molecule drugs. By modulating the host’s microecological environment—such as the gut, skin, or respiratory tract—these therapies aim to restore immune balance, regulate metabolism, and treat a broad spectrum of diseases including infectious conditions, inflammatory bowel diseases, metabolic disorders, neuropsychiatric illnesses, and cancers. As breakthroughs in microbiome science and synthetic biology continue to accelerate, microbiome drugs are emerging as a core pillar of precision medicine—transforming treatment paradigms from "killing microbes" to "leveraging microbes" for systemic therapeutic benefit.
As the concept of precision medicine continues to evolve globally, microbiome drugs are rapidly emerging as a new strategic frontier in biopharmaceutical innovation. Regulatory authorities in multiple countries have established dedicated review pathways for live microbiome-based products, accelerating clinical translation. According to annual reports from companies several Phase III candidates are approaching commercialization, signaling an imminent market inflection point. Meanwhile, advances in synthetic biology are enabling engineered microbial therapeutics with stable expression platforms, transforming microbiota therapies from fecal transplants into standardized pharmaceuticals. With chronic diseases, immune disorders, and oncology driving demand, global investment and R&D resources are converging toward this transformative sector.
Despite their disruptive potential, microbiome drugs remain in the early adoption phase, facing both technological and regulatory uncertainty. Real-world data reveal high inter-patient variability and inconsistent efficacy in some early-stage products, posing challenges for clinical standardization. Manufacturing, cold-chain logistics, and quality control requirements for live biotherapeutics impose high technical barriers, particularly in scaling up production. In addition, reimbursement frameworks and clinical funding mechanisms are still underdeveloped in many regions, slowing broad market penetration in the short term.
On the demand side, deeper insights into host-microbiome interactions are driving a shift from “supplemental probiotics” to “interventional prescription drugs.” Physicians are increasingly open to microbiome-based therapies, especially for patients with refractory Clostridium difficile infections, ulcerative colitis, autism spectrum disorders, and type 2 diabetes. Leading hospitals are partnering with pharma companies to conduct joint development and real-world studies, fostering a transition from academic trials to routine clinical use. As more candidates reach critical trial milestones, microbiome drugs are poised to establish a distinct and high-potential segment within the global prescription drug market.
This report delivers a comprehensive overview of the global Microbiome Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Microbiome Drugs. The Microbiome Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Microbiome Drugs market comprehensively. Regional market sizes by Type, by Symptom, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Microbiome Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Symptom, and by region.
Market Segmentation
By Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Finch Therapeutics
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
Ferring
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Vedanta Biosciences
Metabogen
Segment by Type
Oral Dosage Form
Enteric Capsules
Segment by Symptom
Gastrointestinal Disorders
Autoimmune Disorders
Diabetes
Cancer
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Symptom, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Microbiome Drugs companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Symptom, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
1.3 Market by Symptom
1.3.1 Global Microbiome Drugs Market Growth by Symptom: 2021 vs 2025 vs 2032
1.3.2 Gastrointestinal Disorders
1.3.3 Autoimmune Disorders
1.3.4 Diabetes
1.3.5 Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Microbiome Drugs Market Perspective (2021–2032)
2.2 Global Microbiome Drugs Growth Trends by Region
2.2.1 Global Microbiome Drugs Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Microbiome Drugs Historic Market Size by Region (2021–2026)
2.2.3 Microbiome Drugs Forecasted Market Size by Region (2027–2032)
2.3 Microbiome Drugs Market Dynamics
2.3.1 Microbiome Drugs Industry Trends
2.3.2 Microbiome Drugs Market Drivers
2.3.3 Microbiome Drugs Market Challenges
2.3.4 Microbiome Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Microbiome Drugs Players by Revenue
3.1.1 Global Top Microbiome Drugs Players by Revenue (2021–2026)
3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2021–2026)
3.2 Global Top Microbiome Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Microbiome Drugs Revenue
3.4 Global Microbiome Drugs Market Concentration Ratio
3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2025
3.5 Global Key Players of Microbiome Drugs Head Offices and Areas Served
3.6 Global Key Players of Microbiome Drugs, Products and Applications
3.7 Global Key Players of Microbiome Drugs, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Microbiome Drugs Breakdown Data by Type
4.1 Global Microbiome Drugs Historic Market Size by Type (2021–2026)
4.2 Global Microbiome Drugs Forecasted Market Size by Type (2027–2032)
5 Microbiome Drugs Breakdown Data by Symptom
5.1 Global Microbiome Drugs Historic Market Size by Symptom (2021–2026)
5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2027–2032)
6 North America
6.1 North America Microbiome Drugs Market Size (2021–2032)
6.2 North America Microbiome Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Microbiome Drugs Market Size by Country (2021–2026)
6.4 North America Microbiome Drugs Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Microbiome Drugs Market Size (2021–2032)
7.2 Europe Microbiome Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Microbiome Drugs Market Size by Country (2021–2026)
7.4 Europe Microbiome Drugs Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Microbiome Drugs Market Size (2021–2032)
8.2 Asia-Pacific Microbiome Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Microbiome Drugs Market Size by Region (2021–2026)
8.4 Asia-Pacific Microbiome Drugs Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Microbiome Drugs Market Size (2021–2032)
9.2 Latin America Microbiome Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Microbiome Drugs Market Size by Country (2021–2026)
9.4 Latin America Microbiome Drugs Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Microbiome Drugs Market Size (2021–2032)
10.2 Middle East & Africa Microbiome Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Microbiome Drugs Market Size by Country (2021–2026)
10.4 Middle East & Africa Microbiome Drugs Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Seres Therapeutics
11.1.1 Seres Therapeutics Company Details
11.1.2 Seres Therapeutics Business Overview
11.1.3 Seres Therapeutics Microbiome Drugs Introduction
11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2021–2026)
11.1.5 Seres Therapeutics Recent Development
11.2 Assembly Biosciences
11.2.1 Assembly Biosciences Company Details
11.2.2 Assembly Biosciences Business Overview
11.2.3 Assembly Biosciences Microbiome Drugs Introduction
11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2021–2026)
11.2.5 Assembly Biosciences Recent Development
11.3 Synthetic Biologics
11.3.1 Synthetic Biologics Company Details
11.3.2 Synthetic Biologics Business Overview
11.3.3 Synthetic Biologics Microbiome Drugs Introduction
11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2021–2026)
11.3.5 Synthetic Biologics Recent Development
11.4 Finch Therapeutics
11.4.1 Finch Therapeutics Company Details
11.4.2 Finch Therapeutics Business Overview
11.4.3 Finch Therapeutics Microbiome Drugs Introduction
11.4.4 Finch Therapeutics Revenue in Microbiome Drugs Business (2021–2026)
11.4.5 Finch Therapeutics Recent Development
11.5 PureTech
11.5.1 PureTech Company Details
11.5.2 PureTech Business Overview
11.5.3 PureTech Microbiome Drugs Introduction
11.5.4 PureTech Revenue in Microbiome Drugs Business (2021–2026)
11.5.5 PureTech Recent Development
11.6 Synlogic
11.6.1 Synlogic Company Details
11.6.2 Synlogic Business Overview
11.6.3 Synlogic Microbiome Drugs Introduction
11.6.4 Synlogic Revenue in Microbiome Drugs Business (2021–2026)
11.6.5 Synlogic Recent Development
11.7 Enterome BioScience
11.7.1 Enterome BioScience Company Details
11.7.2 Enterome BioScience Business Overview
11.7.3 Enterome BioScience Microbiome Drugs Introduction
11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2021–2026)
11.7.5 Enterome BioScience Recent Development
11.8 4D Pharma
11.8.1 4D Pharma Company Details
11.8.2 4D Pharma Business Overview
11.8.3 4D Pharma Microbiome Drugs Introduction
11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2021–2026)
11.8.5 4D Pharma Recent Development
11.9 Second Genome
11.9.1 Second Genome Company Details
11.9.2 Second Genome Business Overview
11.9.3 Second Genome Microbiome Drugs Introduction
11.9.4 Second Genome Revenue in Microbiome Drugs Business (2021–2026)
11.9.5 Second Genome Recent Development
11.10 Ferring
11.10.1 Ferring Company Details
11.10.2 Ferring Business Overview
11.10.3 Ferring Microbiome Drugs Introduction
11.10.4 Ferring Revenue in Microbiome Drugs Business (2021–2026)
11.10.5 Ferring Recent Development
11.11 C3 Jian
11.11.1 C3 Jian Company Details
11.11.2 C3 Jian Business Overview
11.11.3 C3 Jian Microbiome Drugs Introduction
11.11.4 C3 Jian Revenue in Microbiome Drugs Business (2021–2026)
11.11.5 C3 Jian Recent Development
11.12 Rebiotix
11.12.1 Rebiotix Company Details
11.12.2 Rebiotix Business Overview
11.12.3 Rebiotix Microbiome Drugs Introduction
11.12.4 Rebiotix Revenue in Microbiome Drugs Business (2021–2026)
11.12.5 Rebiotix Recent Development
11.13 MicroBiome Therapeutics LLC
11.13.1 MicroBiome Therapeutics LLC Company Details
11.13.2 MicroBiome Therapeutics LLC Business Overview
11.13.3 MicroBiome Therapeutics LLC Microbiome Drugs Introduction
11.13.4 MicroBiome Therapeutics LLC Revenue in Microbiome Drugs Business (2021–2026)
11.13.5 MicroBiome Therapeutics LLC Recent Development
11.14 Metabiomics
11.14.1 Metabiomics Company Details
11.14.2 Metabiomics Business Overview
11.14.3 Metabiomics Microbiome Drugs Introduction
11.14.4 Metabiomics Revenue in Microbiome Drugs Business (2021–2026)
11.14.5 Metabiomics Recent Development
11.15 Ritter Pharmaceuticals
11.15.1 Ritter Pharmaceuticals Company Details
11.15.2 Ritter Pharmaceuticals Business Overview
11.15.3 Ritter Pharmaceuticals Microbiome Drugs Introduction
11.15.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2021–2026)
11.15.5 Ritter Pharmaceuticals Recent Development
11.16 Symberix
11.16.1 Symberix Company Details
11.16.2 Symberix Business Overview
11.16.3 Symberix Microbiome Drugs Introduction
11.16.4 Symberix Revenue in Microbiome Drugs Business (2021–2026)
11.16.5 Symberix Recent Development
11.17 OpenBiome
11.17.1 OpenBiome Company Details
11.17.2 OpenBiome Business Overview
11.17.3 OpenBiome Microbiome Drugs Introduction
11.17.4 OpenBiome Revenue in Microbiome Drugs Business (2021–2026)
11.17.5 OpenBiome Recent Development
11.18 Azitra
11.18.1 Azitra Company Details
11.18.2 Azitra Business Overview
11.18.3 Azitra Microbiome Drugs Introduction
11.18.4 Azitra Revenue in Microbiome Drugs Business (2021–2026)
11.18.5 Azitra Recent Development
11.19 Symbiotix Biotherapies
11.19.1 Symbiotix Biotherapies Company Details
11.19.2 Symbiotix Biotherapies Business Overview
11.19.3 Symbiotix Biotherapies Microbiome Drugs Introduction
11.19.4 Symbiotix Biotherapies Revenue in Microbiome Drugs Business (2021–2026)
11.19.5 Symbiotix Biotherapies Recent Development
11.20 Vedanta Biosciences
11.20.1 Vedanta Biosciences Company Details
11.20.2 Vedanta Biosciences Business Overview
11.20.3 Vedanta Biosciences Microbiome Drugs Introduction
11.20.4 Vedanta Biosciences Revenue in Microbiome Drugs Business (2021–2026)
11.20.5 Vedanta Biosciences Recent Development
11.21 Metabogen
11.21.1 Metabogen Company Details
11.21.2 Metabogen Business Overview
11.21.3 Metabogen Microbiome Drugs Introduction
11.21.4 Metabogen Revenue in Microbiome Drugs Business (2021–2026)
11.21.5 Metabogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Oral Dosage Form
Table 3. Key Players of Enteric Capsules
Table 4. Global Microbiome Drugs Market Size Growth by Symptom (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Microbiome Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Microbiome Drugs Market Size by Region (US$ Million), 2021–2026
Table 7. Global Microbiome Drugs Market Share by Region (2021–2026)
Table 8. Global Microbiome Drugs Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Microbiome Drugs Market Share by Region (2027–2032)
Table 10. Microbiome Drugs Market Trends
Table 11. Microbiome Drugs Market Drivers
Table 12. Microbiome Drugs Market Challenges
Table 13. Microbiome Drugs Market Restraints
Table 14. Global Microbiome Drugs Revenue by Players (US$ Million), 2021–2026
Table 15. Global Microbiome Drugs Market Share by Players (2021–2026)
Table 16. Global Top Microbiome Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Microbiome Drugs Revenue, 2025
Table 17. Ranking of Global Top Microbiome Drugs Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Microbiome Drugs Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Microbiome Drugs, Headquarters and Area Served
Table 20. Global Key Players of Microbiome Drugs, Products and Applications
Table 21. Global Key Players of Microbiome Drugs, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Microbiome Drugs Market Size by Type (US$ Million), 2021–2026
Table 24. Global Microbiome Drugs Revenue Market Share by Type (2021–2026)
Table 25. Global Microbiome Drugs Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Microbiome Drugs Revenue Market Share by Type (2027–2032)
Table 27. Global Microbiome Drugs Market Size by Symptom (US$ Million), 2021–2026
Table 28. Global Microbiome Drugs Revenue Market Share by Symptom (2021–2026)
Table 29. Global Microbiome Drugs Forecasted Market Size by Symptom (US$ Million), 2027–2032
Table 30. Global Microbiome Drugs Revenue Market Share by Symptom (2027–2032)
Table 31. North America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Microbiome Drugs Market Size by Country (US$ Million), 2021–2026
Table 33. North America Microbiome Drugs Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Microbiome Drugs Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Microbiome Drugs Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Microbiome Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Microbiome Drugs Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Microbiome Drugs Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Microbiome Drugs Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Microbiome Drugs Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Microbiome Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Microbiome Drugs Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Microbiome Drugs Market Size by Country (US$ Million), 2027–2032
Table 46. Seres Therapeutics Company Details
Table 47. Seres Therapeutics Business Overview
Table 48. Seres Therapeutics Microbiome Drugs Product
Table 49. Seres Therapeutics Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 50. Seres Therapeutics Recent Development
Table 51. Assembly Biosciences Company Details
Table 52. Assembly Biosciences Business Overview
Table 53. Assembly Biosciences Microbiome Drugs Product
Table 54. Assembly Biosciences Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 55. Assembly Biosciences Recent Development
Table 56. Synthetic Biologics Company Details
Table 57. Synthetic Biologics Business Overview
Table 58. Synthetic Biologics Microbiome Drugs Product
Table 59. Synthetic Biologics Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 60. Synthetic Biologics Recent Development
Table 61. Finch Therapeutics Company Details
Table 62. Finch Therapeutics Business Overview
Table 63. Finch Therapeutics Microbiome Drugs Product
Table 64. Finch Therapeutics Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 65. Finch Therapeutics Recent Development
Table 66. PureTech Company Details
Table 67. PureTech Business Overview
Table 68. PureTech Microbiome Drugs Product
Table 69. PureTech Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 70. PureTech Recent Development
Table 71. Synlogic Company Details
Table 72. Synlogic Business Overview
Table 73. Synlogic Microbiome Drugs Product
Table 74. Synlogic Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 75. Synlogic Recent Development
Table 76. Enterome BioScience Company Details
Table 77. Enterome BioScience Business Overview
Table 78. Enterome BioScience Microbiome Drugs Product
Table 79. Enterome BioScience Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 80. Enterome BioScience Recent Development
Table 81. 4D Pharma Company Details
Table 82. 4D Pharma Business Overview
Table 83. 4D Pharma Microbiome Drugs Product
Table 84. 4D Pharma Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 85. 4D Pharma Recent Development
Table 86. Second Genome Company Details
Table 87. Second Genome Business Overview
Table 88. Second Genome Microbiome Drugs Product
Table 89. Second Genome Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 90. Second Genome Recent Development
Table 91. Ferring Company Details
Table 92. Ferring Business Overview
Table 93. Ferring Microbiome Drugs Product
Table 94. Ferring Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 95. Ferring Recent Development
Table 96. C3 Jian Company Details
Table 97. C3 Jian Business Overview
Table 98. C3 Jian Microbiome Drugs Product
Table 99. C3 Jian Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 100. C3 Jian Recent Development
Table 101. Rebiotix Company Details
Table 102. Rebiotix Business Overview
Table 103. Rebiotix Microbiome Drugs Product
Table 104. Rebiotix Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 105. Rebiotix Recent Development
Table 106. MicroBiome Therapeutics LLC Company Details
Table 107. MicroBiome Therapeutics LLC Business Overview
Table 108. MicroBiome Therapeutics LLC Microbiome Drugs Product
Table 109. MicroBiome Therapeutics LLC Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 110. MicroBiome Therapeutics LLC Recent Development
Table 111. Metabiomics Company Details
Table 112. Metabiomics Business Overview
Table 113. Metabiomics Microbiome Drugs Product
Table 114. Metabiomics Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 115. Metabiomics Recent Development
Table 116. Ritter Pharmaceuticals Company Details
Table 117. Ritter Pharmaceuticals Business Overview
Table 118. Ritter Pharmaceuticals Microbiome Drugs Product
Table 119. Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 120. Ritter Pharmaceuticals Recent Development
Table 121. Symberix Company Details
Table 122. Symberix Business Overview
Table 123. Symberix Microbiome Drugs Product
Table 124. Symberix Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 125. Symberix Recent Development
Table 126. OpenBiome Company Details
Table 127. OpenBiome Business Overview
Table 128. OpenBiome Microbiome Drugs Product
Table 129. OpenBiome Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 130. OpenBiome Recent Development
Table 131. Azitra Company Details
Table 132. Azitra Business Overview
Table 133. Azitra Microbiome Drugs Product
Table 134. Azitra Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 135. Azitra Recent Development
Table 136. Symbiotix Biotherapies Company Details
Table 137. Symbiotix Biotherapies Business Overview
Table 138. Symbiotix Biotherapies Microbiome Drugs Product
Table 139. Symbiotix Biotherapies Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 140. Symbiotix Biotherapies Recent Development
Table 141. Vedanta Biosciences Company Details
Table 142. Vedanta Biosciences Business Overview
Table 143. Vedanta Biosciences Microbiome Drugs Product
Table 144. Vedanta Biosciences Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 145. Vedanta Biosciences Recent Development
Table 146. Metabogen Company Details
Table 147. Metabogen Business Overview
Table 148. Metabogen Microbiome Drugs Product
Table 149. Metabogen Revenue in Microbiome Drugs Business (US$ Million), 2021–2026
Table 150. Metabogen Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report
List of Figures
Figure 1. Microbiome Drugs Picture
Figure 2. Global Microbiome Drugs Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Microbiome Drugs Market Share by Type: 2025 vs 2032
Figure 4. Oral Dosage Form Features
Figure 5. Enteric Capsules Features
Figure 6. Global Microbiome Drugs Market Size by Symptom (US$ Million), 2021–2032
Figure 7. Global Microbiome Drugs Market Share by Symptom: 2025 vs 2032
Figure 8. Gastrointestinal Disorders Case Studies
Figure 9. Autoimmune Disorders Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Cancer Case Studies
Figure 12. Others Case Studies
Figure 13. Microbiome Drugs Report Years Considered
Figure 14. Global Microbiome Drugs Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Microbiome Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Microbiome Drugs Market Share by Region: 2025 vs 2032
Figure 17. Global Microbiome Drugs Market Share by Players in 2025
Figure 18. Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Microbiome Drugs Revenue in 2025
Figure 20. North America Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Microbiome Drugs Market Share by Country (2021–2032)
Figure 22. United States Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Microbiome Drugs Market Share by Country (2021–2032)
Figure 26. Germany Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Microbiome Drugs Market Share by Region (2021–2032)
Figure 34. China Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Microbiome Drugs Market Share by Country (2021–2032)
Figure 42. Mexico Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Microbiome Drugs Market Share by Country (2021–2032)
Figure 46. Israel Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Microbiome Drugs Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Seres Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 50. Assembly Biosciences Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 51. Synthetic Biologics Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 52. Finch Therapeutics Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 53. PureTech Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 54. Synlogic Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 55. Enterome BioScience Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 56. 4D Pharma Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 57. Second Genome Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 58. Ferring Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 59. C3 Jian Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 60. Rebiotix Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 61. MicroBiome Therapeutics LLC Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 62. Metabiomics Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 63. Ritter Pharmaceuticals Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 64. Symberix Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 65. OpenBiome Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 66. Azitra Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 67. Symbiotix Biotherapies Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 68. Vedanta Biosciences Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 69. Metabogen Revenue Growth Rate in Microbiome Drugs Business (2021–2026)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
